-
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: theoretical and empirical considerations.
Tong YK, Ding C, Chiu RW, Gerovassili A, Chim SS, Leung TY, Leung TN, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2006;52:2194-202. -
Cell-free DNA levels in pregnancies at risk of sickle-cell disease and significant ethnic variation.
Gerovassili A, Nicolaides KH, Thein SL, Rees DC.
Br J Haematol 2006;135:738-41. -
Detection of trisomy 21 by quantitative mass spectrometric analysis of single-nucleotide polymorphisms.
Tsui NB, Chiu RW, Ding C, El-Sheikhah A, Leung TN, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2005;51:2358-62. -
Comparison of protocols for extracting circulating DNA and RNA from maternal plasma.
Chiu RW, Lui WB, El-Sheikhah A, Chan AT, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2005;51:2209-10. -
First trimester maternal serum placenta growth factor (PlGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
Prenat Diagn 2001;21:718-22. -
First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction.
Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH.
Obstet Gynecol 2001;98:608-11.